Navigation Links
Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Date:1/8/2008

SAN MATEO, Calif., Jan. 8 /PRNewswire/ -- Corthera Inc. today announced the initiation of patient enrollment in a Phase II clinical trial of Relaxin, a naturally occurring peptide hormone that is being developed for acute heart failure and other acute care illnesses.

The trial will investigate the efficacy and safety of Relaxin in patients with acute heart failure. Approximately 330 patients will be recruited from more than 50 investigational centers worldwide. The primary outcome measure is the improvement of clinical signs and symptoms of acute heart failure, with additional secondary outcome measures, including improvement in renal function.

"With the current lack of safe and effective therapies for acute heart failure, we are very pleased to advance the development of Relaxin for the benefit of these patients," said Stan E. Abel, president and chief executive officer of Corthera. "The clinical and preclinical results to date are very encouraging, demonstrating Relaxin's beneficial hemodynamic properties."

According to the American Heart Association, heart failure is a costly cardiac and renal syndrome affecting more than 550,000 new patients per year, with projected direct and indirect costs at $33.2 billion in 2007. Acute heart failure is characterized by fluid overload (congestion), especially in the lungs, that causes shortness of breath and other complications. The current standard of care includes diuretics and vasodilators. Diuretics, which promote fluid excretion, are associated with renal complications. Vasodilators tested to date have been linked to hypotension, renal impairment and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a targeted vasodilator with demonstrated systemic and renal hemodynamic effects. Elevated levels of Relaxin are thought to modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent
'/>"/>

SOURCE Corthera Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
3. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
7. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
8. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
9. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Wrightington, Wigan and Leigh ... MDRX ) are delighted to announce WWL,s decision to ... information system. The system will be implemented across all ... WWL delivers healthcare in the future. ... on-time and on-budget system implementations as well as its ...
(Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
(Date:9/30/2014)... 30, 2014  According to their CEO, ... clinical trials is going through a complete transformation ... work of the current clinical trial management process ... generation, clinical trials, which will ultimately drive the ... The company has been recognized by the National ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Calif., May 3, 2012 Alarm bells are ringing ... proportions worldwide, triggering intensive ophthalmic research into vision-compromising comorbidities. ... diabetic retinopathy will triple from 5.5 million in 2005 ... leading cause of blindness in working age people, improved ...
... Dutch Medical Brands receives first European ... traditional treatment with antibiotics, bladder and urinary tract infections ... effects. Dutch company Medical Brands has obtained a Class ... making it the first and only cranberry-based product in ...
Cached Medicine Technology:Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant 2Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant 3Cranberry Capsule Proven to Cure Bladder Infection 2
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... News) -- Elevated blood levels of a central nervous system ... by a lack of oxygen, according to a new study. ... can also help doctors assess the effectiveness of a body-cooling ... Johns Hopkins researchers said. GFAP is specific to central ...
... HealthDay Reporter , THURSDAY, Oct. 13 (HealthDay News) ... epilepsy remain free of seizures 10 years later, a new ... medication, and only when drugs can,t control seizures -- often ... for surgery. This study suggests that some patients with focal ...
... procedure that measures the amount of oxygen in the ... detect critical congenital heart disease (CCHD) in infants, and ... standard for CCHD diagnosis, according to a new research ... of Pediatrics (AAP) National Conference and Exhibition (NCE) in ...
... THURSDAY, Oct. 13 (HealthDay News) -- Smoky, inefficient indoor cooking ... developing nations contribute to 2 million deaths a year, according ... affects about 3 billion people, or nearly half the world,s ... in a commentary published in the current issue of the ...
... CHAMPAIGN, Ill. What if you could trace the history of ... camera, you could learn what factory made the ingredients in your ... or even how to recycle the phone. You could follow the ... along the way to ensure that the medicine you,re taking isn,t ...
... 13 (HealthDay News) -- Nearly one in four Americans with ... undiagnosed psoriatic arthritis, according to a new study. This ... United States who have been diagnosed with the disease, a ... and can lead to joint destruction and disability. For ...
Cached Medicine News:Health News:Protein May Help Spot Newborns With Brain Damage 2Health News:For Many, Epilepsy Surgery Effective Long-Term 2Health News:For Many, Epilepsy Surgery Effective Long-Term 3Health News:Globally, 2 Million Deaths a Year Linked to Smoky Stoves 2Health News:Packaging expert sees a social revolution in the evolving barcode 2Health News:Packaging expert sees a social revolution in the evolving barcode 3Health News:1 in 4 With Psoriasis May Have Undiagnosed Arthritis 2
... a 28 amino-acid lipophilic peptide with a ... serine residue three, that is primarily expressed ... the mucosa of the fundus of the ... to those of leptin. Ghrelin stimulates food ...
... The Medtronic SelectSecure Lead System (Model 3830) ... Its unique, lumenless design allows for flexibility ... without sacrificing insulation thickness. The SelectSecure lead ... positioning of the lead in select locations ...
... Human sex hormone-binding globulin (SHBG) is ... steroids with relatively high specificity and low ... bound to SHBG) and, to a much ... C18 and C19 steroid structures and regulates ...
... is the glucuronide conjugate of 3alpha-androstanediol, ... [1,2]. 3alpha-diol G has strong androgenic ... bioactivity of testosterone [2]. Serum 3alpha-diol ... reduction of DHT, and in addition, ...
Medicine Products: